연구동향 분석

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

이현정 허대석 조주연 한세원 장혜정 이현규 김태은 이세훈 오도연 임석아 장인진 방영주 2014년

논문상세정보
인용/피인용
' A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • administration
  • clinical trial
  • oral
  • p-glycoprotein
  • paclitaxel
  • pharmacokinetics
  • phase1
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,592 0

0.0%

' A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer' 의 참고문헌

  • Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Baird RD Nat Rev Clin Oncol 7 : 575 ~ 582 [2010]
  • Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Baird RD Nat Rev Clin Oncol 7 575-582 [2010]
  • Weekly paclitaxel in the adjuvant treatment of breast cancer
    Sparano JA N Engl J Med 358 : 1663 ~ 1671 [2008]
  • Weekly paclitaxel in the adjuvant treatment of breast cancer
    Sparano JA N Engl J Med 358 1663-1671 [2008]
  • Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies
    Kim TE Clin Ther 34 : 482 ~ 494 [2012]
  • Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies
    Kim TE Clin Ther 34 482-494 [2012]
  • Theoretical concepts and the emerging role of taxanes in adjuvant therapy
    Norton L Oncologist 6 Suppl 3 : 30 ~ 35 [2001]
  • Theoretical concepts and the emerging role of taxanes in adjuvant therapy
    Norton L Oncologist 6 Suppl 3 30-35 [2001]
  • Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM- 30181 in rat plasma by liquid chromatography with tandem mass spectrometry
    Paek IB J Sep Sci 29 : 628 ~ 634 [2006]
  • Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM- 30181 in rat plasma by liquid chromatography with tandem mass spectrometry
    Paek IB J Sep Sci 29 628-634 [2006]
  • Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel
    Kwak JO Eur J Pharmacol 627 : 92 ~ 98 [2010]
  • Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel
    Kwak JO Eur J Pharmacol 627 92-98 [2010]
  • Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
    Cascorbi I Pharmacol Ther 112 : 457 ~ 473 [2006]
  • Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
    Cascorbi I Pharmacol Ther 112 457-473 [2006]
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840
    Seidman AD J Clin Oncol 26 : 1642 ~ 1649 [2008]
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840
    Seidman AD J Clin Oncol 26 1642-1649 [2008]
  • Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs
    Bocci G Cancer Res 62 : 6938 ~ 6943 [2002]
  • Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs
    Bocci G Cancer Res 62 6938-6943 [2002]
  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor- free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    Kim TY Clin Cancer Res 10 : 3708 ~ 3716 [2004]
  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor- free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    Kim TY Clin Cancer Res 10 3708-3716 [2004]
  • Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
    Ibrahim NK Clin Cancer Res 8 : 1038 ~ 1044 [2002]
  • Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
    Ibrahim NK Clin Cancer Res 8 1038-1044 [2002]
  • Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
    Kobayashi M Gastric Cancer 10 : 52 ~ 57 [2007]
  • Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
    Kobayashi M Gastric Cancer 10 52-57 [2007]
  • Paclitaxel(taxol)
    Rowinsky EK N Engl J Med 332 1004-1014 [1995]
  • Paclitaxel (taxol)
    Rowinsky EK N Engl J Med 332 : 1004 ~ 1014 [1995]
  • P-glycoprotein inhibition : the past, the present and the future
    Darby RA Curr Drug Metab 12 : 722 ~ 731 [2011]
  • P-glycoprotein inhibition : the past, the present and the future
    Darby RA Curr Drug Metab 12 722-731 [2011]
  • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse P J Natl Cancer Inst 92 205-216 [2000]
  • New guidelines to evaluate the response to treatment in solid tumors : European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse P J Natl Cancer Inst 92 : 205 ~ 216 [2000]
  • Metronomic chemotherapy : new rationale for new directions
    Pasquier E Nat Rev Clin Oncol 7 : 455 ~ 465 [2010]
  • Metronomic chemotherapy : new rationale for new directions
    Pasquier E Nat Rev Clin Oncol 7 455-465 [2010]
  • Limited oral bioavailability and active epithelial excretion of paclitaxel(Taxol)caused by P-glycoprotein in the intestine
    Sparreboom A Proc Natl Acad Sci U S A 94 : 2031 ~ 2035 [1997]
  • Limited oral bioavailability and active epithelial excretion of paclitaxel(Taxol)caused by P-glycoprotein in the intestine
    Sparreboom A Proc Natl Acad Sci U S A 94 2031-2035 [1997]
  • Cremophor EL : the drawbacks and advantages of vehicle selection for drug formulation
    Gelderblom H Eur J Cancer 37 : 1590 ~ 1598 [2001]
  • Cremophor EL : the drawbacks and advantages of vehicle selection for drug formulation
    Gelderblom H Eur J Cancer 37 1590-1598 [2001]
  • Confidence interval criteria for assessment of dose proportionality
    Smith BP Pharm Res 17 : 1278 ~ 1283 [2000]
  • Confidence interval criteria for assessment of dose proportionality
    Smith BP Pharm Res 17 1278-1283 [2000]
  • Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
    National Cancer Institute
  • Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
    Malingre MM Br J Cancer 84 : 42 ~ 47 [2001]
  • Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
    Malingre MM Br J Cancer 84 42-47 [2001]
  • A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
    Hong YS Invest New Drugs 31 : 616 ~ 622 [2013]
  • A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
    Hong YS Invest New Drugs 31 616-622 [2013]
  • A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Broker LE Clin Cancer Res 13 : 3906 ~ 3912 [2007]
  • A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Broker LE Clin Cancer Res 13 3906-3912 [2007]
  • A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A
    Malingre MM Cancer Chemother Pharmacol 47 : 347 ~ 354 [2001]
  • A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A
    Malingre MM Cancer Chemother Pharmacol 47 347-354 [2001]